FBLG
FibroBiologics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$1.81
+2.56%Aug 27, 2026, 12:30 UTC
FibroBiologics released the third batch of its CYWC628 drug product and shipped it to Australia to support its ongoing Phase 1/2 clinical trial for diabetic foot ulcers.
Aug 24, 2026, 00:00 UTC
FibroBiologics, Inc. appointed Leigh Steinberg as a Class II director of its Board of Directors, effective August 20, 2026.
Aug 20, 2026, 12:30 UTC
FibroBiologics announced that IP Australia accepted its Australian patent application for a cannabidiol adjuvant therapy for treating degenerative disc disease.
Source:Aug 11, 2026, 12:30 UTC
FibroBiologics announced that the USPTO issued U.S. Patent No. 12,691,147 covering the use of fibroblasts to enhance survival and function of transplanted insulin-producing islets, with potential applications beyond diabetes.
Source:Aug 5, 2026, 12:30 UTC
FibroBiologics announced that the European Patent Office granted its patent for gene therapy for cartilage regeneration, covering Sox9-based conversion of fibroblasts into cartilage-producing cells.
Source:Jul 31, 2026, 21:34 UTC
FibroBiologics reported its financial results for the second quarter ended June 30, 2026.
Source:Jul 9, 2026, 00:00 UTC
Kathleen Rubins, Ph.D. was appointed as a Class III director of the Board of Directors of FibroBiologics, Inc., effective July 8, 2026.
Jul 9, 2026, 00:00 UTC
Matt Link resigned from the Board of Directors of FibroBiologics, Inc., effective July 2, 2026.
Jul 7, 2026, 12:30 UTC
FibroBiologics completed manufacturing of the third batch of its CYWC628 drug product for a Phase 1/2 clinical trial in patients with diabetic foot ulcers.
Source:Jun 3, 2026, 11:00 UTC
FibroBiologics dosed the first patients in a Phase 1/2 clinical trial of CYWC628 for diabetic foot ulcers.